| Literature DB >> 32660472 |
Jiao-Xia Wu1, An Jia2,3, Yin-Feng Tan1, Han Xu1, Jian-Ping Tian1, Yan Wang1, Hai Long Li1, Bing-Miao Gao1, Yong-Hui Li4,5.
Abstract
BACKGROUND: Abnormal renal metabolism is closely related to the development of chronic kidney disease. It is well known that renal inflammation plays an important role in the occurrence and development of tubulointerstitial damage in the renal tubules. The purpose of the experiment was to observe the bioactivity of Alpina oxyphylla extract (AOE) on renal injury in diabetic nephropathy (DN) rats induced by streptozotocin (STZ).Entities:
Keywords: Alpina oxyphylla; Diabetic nephropathy; MyD88; TGF-β1
Mesh:
Substances:
Year: 2020 PMID: 32660472 PMCID: PMC7359227 DOI: 10.1186/s12906-020-02972-x
Source DB: PubMed Journal: BMC Complement Med Ther ISSN: 2662-7671
Fig. 1Histological study of H&E staining in rat kidney sections (200× magnification). a not-diabetic group: a small amount of eosinophilic substance in the local capsular space (black arrow); b STZ-induced diabetic rats group: cytoplasmic vacuolation of renal tubular epithelium, renal tubular dilation (black arrow); c Glechide-treated drug group; d AOE treatment (800 mg/kg) group: cytoplasmic vacuolation of renal tubular epithelial cells (black arrow); e AOE treatment (400 mg/kg) group: occasionally there is a small amount of eosinophilic substance in the renal capsule (yellow arrow). cytoplasmic vacuolation of renal tubular epithelial cells (black arrow)
Comparison of 24 h urine prtein, body weight and kidney weight (mean ± SD, n = 6)
| Nomal | STZ | STZ-gli | AOE 800 | AOE 400 | |
|---|---|---|---|---|---|
| Urine protein (μg/24 h) | 2100.01 ± 721.38 | 3490.23 ± 1961.51* | 118.85 ± 241.15## | 1630.36 ± 491.78# | 1432.48 ± 430.51# |
| Weight initial (g) | 258.50 ± 81.90 | 201.86 ± 18.11 | 212.29 ± 9.69 | 216.57 ± 8.08 | 202.57 ± 15.31 |
| Weight final (g) | 383.12 ± 34.33 | 164.83 ± 20.47** | 205.83 ± 16.51# | 213.80 ± 7.40# | 208.17 ± 4.07# |
| Kidney weight (g) | 1.155 ± 1.1032 | 0.914 ± 0.092** | 1.024 ± 0.075# | 1.030 ± 0.091# | 1.038 ± 0.086# |
Compared with the normal group, *P < 0.05, ** < 0.01
Compared with the STZ group, #P < 0.05, ## < 0.01
Average blood glucose concentration (x ± SD, mmol / L)
| Group | Number | 1 week | 3 weeks | 6 weeks |
|---|---|---|---|---|
| Normal | 6 | 6.68 ± 0.71 | 13.10 ± 5.17 | 5.15 ± 0.63 |
| STZ | 6 | 22.21 ± 4.04** | 33.07 ± 0.57** | 21.27 ± 5.34** |
| STZ-gli | 6 | 16.70 ± 7.84 | 29.57 ± 2.23 | 9.90 ± 2.14# |
| AOE 800 | 6 | 14.86 ± 6.66 | 30.78 ± 4.30 | 9.23 ± 2.71# |
| AOE 400 | 6 | 22.00 ± 5.44 | 25.71 ± 2.03## | 10.86 ± 6.27# |
Compared with the normal group, **P < 0.01
Compared with the STZ group, #P < 0.05, ## < 0.01
Comparison of renal function parameters in rats (mean ± SD, n = 6)
| Nomal | STZ | STZ-gli | AOE 800 | AOE 400 | |
|---|---|---|---|---|---|
| Scr (umol/L) | 90.12 ± 4.90 | 125.32 ± 7.05** | 112.4 ± 12.36 | 107.83 ± 11.66## | 140.82 ± 8.32# |
| BUN (mmol/L) | 4.60 ± 0.99 | 13.64 ± 3.54** | 9.77 ± 2.42# | 9.53 ± 2.38## | 13.04 ± 2.52 |
| TG (mmol/L) | 0.11 ± 0.04 | 0.14 ± 0.10* | 0.19 ± 0.07 | 0.07 ± 0.01## | 0.11 ± 0.05 |
| TC (mmol/L) | 1.62 ± 0.29 | 3.88 ± 0.68 | 2.24 ± 0.21# | 1.52 ± 0.21## | 2.08 ± 0.42## |
| HDL-C (mmol/L) | 0.58 ± 0.11 | 1.27 ± 0.17** | 0.79 ± 0.14## | 0.85 ± 0.09## | 1.06 ± 0.12# |
| GSH (umol/L) | 21.20 ± 0.37 | 22.80 ± 1.20 | 19.07 ± 1.44## | 19.10 ± 1.57## | 21.86 ± 1.74 |
| IL-6 (pg/mL) | 0.43 ± 0.05# | 0.49 ± 0.10* | 0.44 ± 0.04# | 0.41 ± 0.03## | 0.40 ± 0.03## |
Compared with the normal group, *P < 0.05, ** < 0.01
Compared with the STZ group, #P < 0.05, ## < 0.01
Fig. 2Effect of AOE treatment on the expression of TGF-β1, and MyD88 in renal tissue of STZ-diabetic rats. (A) normal group, (B) STZ-induced diabetic rats group, (C) Glechide-treated drug group, (D) AOE treatment (800 mg/kg) group, (E) AOE treatment (400 mg/kg) group. Compared with the ND group, *P < 0.05, **P < 0.01; Compared with the STZ group, #P < 0.05, ##P < 0.01